Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study

Conclusions: For LT recipients with recurrent advanced HCV and at greatest need of cure, protease inhibitor–based triple therapy achieved approximately 50% SVR12. However, there is significant risk of serious adverse events, arguing for earlier intervention. The availability of treatments with better efficacy and safety is of particular importance for posttransplant patients with advanced disease.
Source: Transplantation - Category: Transplant Surgery Tags: Original Clinical Science-Liver Source Type: research